Has Palivizumab prophylaxis effect on long time protection cystic fibrosis children from infections?

A. Folino (Torino, Italy), M. Fissore (Novara, Italy), I. Stura (Torino, Italy), F. Del Monte (Torino, Italy), I. Castagno (Novara, Italy), I. Esposito (Torino, Italy), E. Bignamini (Torino, Italy)

Source: International Congress 2019 – Infection and inflammation in cystic fibrosis
Session: Infection and inflammation in cystic fibrosis
Session type: Thematic Poster
Number: 982
Disease area: Paediatric lung diseases, Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Folino (Torino, Italy), M. Fissore (Novara, Italy), I. Stura (Torino, Italy), F. Del Monte (Torino, Italy), I. Castagno (Novara, Italy), I. Esposito (Torino, Italy), E. Bignamini (Torino, Italy). Has Palivizumab prophylaxis effect on long time protection cystic fibrosis children from infections?. 982

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Viral infections trigger exacerbations of cystic fibrosis in adults and children
Source: Eur Respir J 2012; 40: 510-512
Year: 2012


Palivizumab prophylaxis for respiratory syncytial virus (RSV) in infants with cystic fibrosis (CF) and respiratory illness hospitalizations
Source: International Congress 2015 – Paediatric pulmonary infections
Year: 2015


Palivizumab: Is it cost effective to extend the vaccination period for patients at risk of severe respiratory syncytial virus infection?
Source: Virtual Congress 2021 – Acute and chronic lung infections in children
Year: 2021



The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 486s
Year: 2006

LATE-BREAKING ABSTRACT: Is there a relationship between use of inhaled antibiotics and prevalence of fungal isolates in the respiratory secretions of people with cystic fibrosis? A retrospective data analysis
Source: International Congress 2015 – Cystic fibrosis: assessment and treatment
Year: 2015



The effect of palivizumab prophylaxis on serious early childhood wheezing
Source: Annual Congress 2009 - Diagnosis and treatment of viral respiratory infections in early childhood
Year: 2009

Usefulness of long term treatment with azithromycin in patients with bronchiectasis (non cystic fibrosis)
Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections
Year: 2010


Survey of microbiology, pseudomonas eradication and antimicrobial prophylaxis in adult patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Year: 2011


Emerging role of difficult microrganisms in respiratory tract infections of patients with cystic fibrosis with or without lung transplantation
Source: Eur Respir J 2003; 22: Suppl. 45, 514s
Year: 2003

Emerging pathogens in cystic fibrosis
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66
Year: 2006

Longitudinal monitoring of sinonasal and oral bacterial reservoirs to prevent chronic lung infection in people with cystic fibrosis
Source: ERJ Open Res, 6 (3) 00115-2020; 10.1183/23120541.00115-2020
Year: 2020



The role of inhaled antibiotics in bronchial infection
Source: Eur Respir Monogr 2013; 60: 120-126
Year: 2013


Audit of management of pseudomonas aeruginosa infection in children with cystic fibrosis
Source: Annual Congress 2009 - Cystic fibrosis: advances in clinical research
Year: 2009


Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe
Source: ERJ Open Res, 7 (4) 00411-2021; 10.1183/23120541.00411-2021
Year: 2021



Efficacy of two different vaccination schemes for influenza annual vaccination in cystic fibrosis patients 3-8-years-old
Source: Eur Respir J 2001; 18: Suppl. 33, 539s
Year: 2001

Is it effective to administer corticosteroids late for neonatal chronic lung disease?
Source: Eur Respir J 2004; 24: Suppl. 48, 620s
Year: 2004

Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection
Source: International Congress 2014 – Cystic fibrosis: assessment and treatment
Year: 2014


Effect of zinc supplementation on respiratory infections in children with cystic fibrosis
Source: Annual Congress 2009 - Host factors in paediatric bacterial respiratory infection
Year: 2009